Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

Participating Faculty

By

October 1st 2002

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

ByEdmund H. Sonnenblick, MD

October 1st 2002

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

ByAndrew Whelton,John G. Fort,Joseph A. Puma,Diane Normandin,Alfonso E. Bello,Kenneth M. Verburg, for the SUCCESS VI Study Group (Reprinted from Th

October 1st 2002

Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination Survey

ByGurkirpal Singh, MD,Jeffrey D. Miller, MS,Fleur H. Lee, MPH,Dan Pettitt, DVM, MSc,Mason W. Russell, MAPE

October 1st 2002

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

BySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MS

October 1st 2002

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

BySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MS

October 1st 2002

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

BySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MS

October 1st 2002

Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

ByEdmund H. Sonnenblick, MD

October 1st 2002

Trending on AJMC

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

5 FAQs: Ebola Outbreaks and the Challenge of Public Trust